Changes in ratio of ineligible use of lamotrigine in Japan based on data from the relief system of the Pharmaceuticals and Medical Devices Agency

Psychiatry Clin Neurosci. 2021 Jan;75(1):27-28. doi: 10.1111/pcn.13156. Epub 2020 Oct 12.

Authors

Kensuke Usui^{1

2}, Kazuo Yamada³, Kouji Okada^{1

2}, Ryusuke Ouchi^{1

2}, Masashi Nibuya³, Ai Takahashi², Yuzo Shito², Yoshiteru Watanabe^{1

2}, Hidehisa Saeki⁴, Eiji Suzuki³

Affiliations

¹ Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
² Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
³ Division of Psychiatry, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
⁴ Department of Dermatology, Nippon Medical School, Tokyo, Japan.

PMID: 32951331
DOI: 10.1111/pcn.13156

No abstract available

Publication types

Letter

MeSH terms

Bipolar Disorder / drug therapy*
Compensation and Redress
Drug and Narcotic Control / statistics & numerical data*
Drug-Related Side Effects and Adverse Reactions / epidemiology*
Epilepsy / drug therapy*
Humans
Japan / epidemiology
Lamotrigine / adverse effects*
Membrane Transport Modulators / adverse effects*

Substances

Membrane Transport Modulators
Lamotrigine